Financial Comparison
Abbott Laboratories vs Becton, Dickinson And Company
Click a ticker to view the full analysis.
In short
Abbott Laboratories is the more profitable of the two, keeping 14.7% of revenue as net profit against 7.7% for Becton, Dickinson And Company. Becton, Dickinson And Company trades at the higher trailing P/E (42.5× vs 31.9× for Abbott Laboratories), so investors pay more for each dollar of its earnings. Fisclear flags 1 medium- or high-severity risk for Abbott Laboratories and 1 for Becton, Dickinson And Company.
Based on filings for periods ending 30 Jun 2026 (ABT) and 30 Jun 2026 (BDX) · Updated
FisclearScore Comparison
FisclearScore is a quantitative model. ABT shown solid · BDX shown dashed. Not financial advice.
| Metric | ABT | BDX |
|---|---|---|
| Price | $98.49 | $182.75 |
| Market Cap | $171.6B | $49.8B |
| P/E (TTM) | 31.9x | 42.5x |
| P/B | 3.3x | 2.0x |
| Beta | 0.58 | 0.28 |
| Div Yield | 2.48% | 2.22% |
| Revenue (TTM) | $44.3B | $21.8B |
| Net Income | $6.5B | $1.7B |
| Gross Margin | — | — |
| Risk Flags | 1 flag | 1 flag |
Related comparisons
Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.